Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
2-Methoxyestradiol, an Endogenous 17β-Estradiol Metabolite, Inhibits Microglial Proliferation and Activation via an Estrogen Receptor-Independent Mechanism.
Impact of oral health in patients with multiple sclerosis and epilepsy: A survey in a neurology clinic.
"Response to the Commentary on "Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin"
Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study.
CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.
Neuromyelitis optica-like pathology is dependent on Type I interferon response.
How embodied is action language? Neurological evidence from motor diseases.
Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis.
Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons.
Neurological disorders and inflammatory bowel diseases.
Neuromyelitis optica mimicking intramedullary tumor.
White matter disease: Longest follow-up of rituximab for neuromyelitis optica.
Errata-corrige. Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis.
Intrathecal immune reset in multiple sclerosis: Exploring a new concept.
Predictors and impact of the working alliance in the neuropsychological rehabilitation of patients with multiple sclerosis.
Multitasking in Multiple Sclerosis: Can it Inform Vocational Functioning?
FTY720 for cancer therapy (Review).
Promoting Remyelination in Multiple Sclerosis-Recent Advances.
Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis.
Systematic review of occupational therapy-related interventions for people with multiple sclerosis: part 1. Activity and participation.
Is customized vestibular rehabilitation effective in patients with multiple sclerosis? A randomized controlled trial.
MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis.
Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.
Analysis of the treatment of neuromyelitis optica.
Neurodegenerative diseases in the era of targeted therapeutics: how to handle a tangled issue.
Pages
« first
‹ previous
…
526
527
528
529
530
531
532
533
534
…
next ›
last »